

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Wadih ARAP  
Renata PASQUALINI

Serial No.: 10/784,537

Filed: February 23, 2004

For: AMINOPEPTIDASE A (APA)  
TARGETING PEPTIDES FOR THE  
TREATMENT OF CANCER

Group Art Unit: 1648

Examiner: Unknown

Atty. Dkt. No.: UTSC:872US

Confirmation No.: 2636

|   |      |
|---|------|
| CERTIFICATE OF ELECTRONIC TRANSMISSION  |      |
| I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below. |      |
| September 12, 2007  | Date |
| David L. Parker   |      |

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

Applicants certify, in accordance with 37 C.F.R. § 1.97(e)(2), that no item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Supplemental Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement.

The required fee in the amount of \$180.00 in connection with the filing of this paper are being charged to a credit card through EFS-Web concurrently with this submission. The Commissioner is hereby authorized to deduct any underpayment of fees or any additional fees required under 37 C.F.R. §§ 1.16 to 1.21 in connection with the filing of this paper from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:872US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,  
  
David L. Parker  
Reg. No. 32,165  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: September 11, 2007